Quris.ai: Revolutionizing Drug Development with AI-Powered Patients-on-a-Chip

quris.ai is a pioneering biopharmaceutical AI company dedicated to transforming drug development by predicting drug safety and efficacy in humans with unprecedented accuracy. By combining cutting-edge machine learning with proprietary "Patients-on-a-Chip" technology—powered by stem-cell-derived miniaturized organs and advanced nano-sensors—the platform enables high-throughput, automated testing that reduces reliance on animal models and accelerates clinical prediction. Backed by top-tier investors and led by Nobel Laureates and industry pioneers, Quris.ai’s BioAI platform is designed to minimize development failures, cut costs, and uphold ESG standards, making it a transformative force in pharmaceutical innovation. The company continues to expand its capabilities through strategic partnerships, including with Merck KGaA and the New York Stem Cell Foundation, and is preparing for clinical testing of its first drug targeting Fragile X syndrome.

Key Features:

• AI-Powered Clinical Prediction: Advanced machine learning models trained on real human biological data to forecast drug safety and efficacy.
• Patients-on-a-Chip Technology: Miniaturized, stem-cell-derived organ systems that simulate human physiological responses.
• Genomic Diversity Simulation: Models reflect broad human genetic variation for more accurate and inclusive predictions.
• High-Throughput Drug Screening: Automated, scalable testing of thousands of drug candidates in parallel.
• Continuous Model Retraining: Real-time data from experiments fuels ongoing AI refinement and improved accuracy.
• Nano-Sensor Monitoring: Next-generation sensors enable real-time, continuous tracking of organ responses to drug exposure.
• Liver and Kidney Toxicity Prediction: Specialized capabilities to detect organ-specific toxicities, particularly liver toxicity.
• Patented Organ-on-Chip Platform: 29 granted and pending patents ensure technological leadership and IP protection.
• Exclusive Collaboration with NYSCF: Partners with a leading stem cell automation institute to enhance testing precision.
• Strategic Industry Partnerships: Expanded collaboration with Merck KGaA, including a five-year exclusive license option for specific disease domains.
• Sustainable & Ethical Development: Aims to eliminate animal testing and promote responsible, human-centric drug discovery.
• Interdisciplinary Innovation: Integrates AI, robotics, life sciences, and medtech for holistic drug evaluation.

Pricing: quris.ai operates under a subscription-based model tailored for enterprise and research partners, with exclusive licensing opportunities available through strategic collaborations.

Conclusion: quris.ai stands at the forefront of AI-driven biopharmaceutical innovation, offering a powerful, ethical, and scalable solution to one of the industry's most persistent challenges—predicting human drug responses. With a world-class team, robust intellectual property, and proven partnerships, it is a game-changer for pharmaceutical research and development.